

## Technology Appraisal Committee Meeting (Committee D)

**Minutes:** Confirmed

**Date and Time:** Thursday 8 March 2018, 10:00-15:10

**Venue:** National Institute for Health and Care Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BT

<b>Present:</b>	1. Professor Gary McVeigh, Chair	Present for all notes
	2. Dr Lindsay Smith, Vice Chair	Present for all notes
	3. Dr Nabeel Alsindi	Present for all notes
	4. Dr Aomesh Bhatt	Present for all notes
	5. Professor David Bowen	Present for all notes
	6. Dr Matthew Bradley	Present for all notes
	7. Mrs Susan Dutton	Present for all notes
	8. Professor Rachel Elliott	Present for all notes
	9. Mrs Gillian Ells	Present for all notes
	10. Professor Paula Ghaneh	Present for notes 10 to 29
	11. Dr Peter Hall	Present for all notes
	12. Rebecca Harmston	Present for all notes
	13. Dr Robert Hodgson	Present for all notes
	14. Libby Mills	Present for all notes
	15. Mr Malcolm Oswald	Present for all notes
	16. Dr Paula Parvulescu	Present for all notes

### In attendance:

Lucy Beggs	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17 to 28
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Professor Peter Clark	CDF Clinical Lead, NHS Expert	Present for all notes
Melanie Costin	Support Services Manager, Patient Expert, nominated by Fight Bladder Cancer	Present for notes 5 to 13
Ross Dent	Technical Analyst, National Institute for Health and Care	Present for notes 1 to 16

	Excellence	
Steve Edwards	ERG representative, BMJ Group	Present for notes 17 to 25
Dr Alastair Greystoke	Senior Lecturer and Honorary Consultant, Clinical Expert, nominated by Pfizer	Present for notes 17 to 25
Christian Griffiths	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 17 to 28
Kayleigh Kew	ERG representative, BMJ Group	Present for notes 17 to 25
Allen Knight	Chair – Action Bladder Cancer UK, Patient Expert, nominated by Action Bladder Cancer UK	Present for notes 5 to 13
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Gemma Marceniuk	ERG representative, BMJ Group	Present for notes 17 to 25
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Kate Ren	ERG representative, School of Health and Related Research (SchARR)	Present for notes 5 to 13
Dr Riyaz Shah	Consultant Medical Oncologist, Clinical Expert, nominated by Roche	Present for notes 17 to 25
Hazel Squires	ERG representative, School of Health and Related Research (SchARR)	Present for notes 5 to 13
Dr Santhanam Sundar	Consultant Oncologist, Clinical Expert, nominated by BUG-	Present for notes 5 to 13

## NCRI-RCP-ACP-RCR

Nwamaka Umeweni	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 16 and note 29
-----------------	---	--

Ashley West	Administrator, National Institute for Health and Care Excellence	Present for all notes
-------------	--	-----------------------

### **Non-public attendees:**

Alexia Campbell-Burton	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
------------------------	---	-----------------------

Sarah Douglas	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 17 to 28
---------------	---	----------------------------

Ann Greenwood	Senior Editor, National Institute for Health and Care Excellence	Present for all notes
---------------	--	-----------------------

Christian Griffiths	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 16
---------------------	---	---------------------------

Hayley Sharpe	Senior Editor, National Institute for Health and Care Excellence	Present for all notes
---------------	--	-----------------------

Maroulla Whitely	Costings, National Institute for Health and Care Excellence	Present for all notes
------------------	---	-----------------------

## **Notes**

### **Welcome**

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable and alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
2. The Chair welcomed Libby Mills to her first meeting as a member of the Appraisal Committee.
3. Apologies were received from Dr Bernard Khoo, Sumithra Maheswaran, Dr David Meads and Professor Oluwafemi Oyeboode.

## **Any other Business**

4. There was no AOB.

## **Appraisal of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209]**

### **Part 1 – Open session**

5. The Chair welcomed the invited experts: Dr Peter Clark, Melanie Costin, Allen Knight, Kate Ren Hazel Squires and Dr Santhanam Sundar to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from Merck Sharp and Dohme to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
  - 7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Rebecca Harmston, Dr Robert Hodgson, Libby Mills, Mr Malcolm Oswald and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.
  - 7.2. Dr Peter Hall declared a non-personal, non-specific financial interest as his department within NHS Lothian had received research funding from Roche and Eli Lilly (comparators).
    - 9.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.
8. The Chair asked all NICE Staff to declare any relevant interests.
  - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 9.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab

for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.

10. The Chair introduced the lead team, Professor Paula Ghaneh, Dr Peter Hall and Dr Rebecca Harmston, who gave presentations on the clinical effectiveness and cost effectiveness of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

14. Discussion on confidential information continued. This information was supplied by the company.
15. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209].
  - 15.1. The committee decision was based on consensus
16. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## **Appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer [ID925]**

### **Part 1 – Open session**

17. The Chair welcomed the invited experts: Dr Peter Clark, Steve Edwards, Dr Alastair Greystoke, Kayleigh Kew, Gemma Marceniuk and Dr Riyaz Shah to the meeting and they introduced themselves to the Committee.
18. The Chair welcomed company representatives from Roche to the meeting.
19. The Chair asked all Committee members to declare any relevant interests
  - 19.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Nabeel Alsindi, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Mrs Susan Dutton, Professor Rachel Elliott, Mrs Gillian Ells, Professor Paula Ghaneh, Rebecca Harmston, Dr Robert Hodgson, Libby Mills, Mr Malcolm Oswald and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal

non-specific family interest for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.

- 19.2. Dr Peter Hall declared a non-personal, non-specific financial interest as his department within NHS Lothian had received research funding from Roche, Pfizer and Eli Lilly (comparators).
  - 9.2.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.
20. The Chair asked all NICE Staff to declare any relevant interests.
  - 20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer [ID925].
21. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
  - 21.1. Dr Peter Clark, Steve Edwards, Dr Alastair Greystoke, Kayleigh Kew and Gemma Marceniuk declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
  - 21.2. Dr Riyaz Shah declared a personal non-specific financial interest as he acts as an advisor to several companies involved in making ALK inhibitors. This involves remunerated roles as an adviser as well as delivering lectures/training. Dr Shah also declared that he is involved with clinical trials of some ALKi agents and has such relationships with Roche, Pfizer, Novartis and Takeda.
    - 21.2.1. It was agreed that this declaration would not prevent Dr Riyaz Shah from participating in this section of the meeting
22. The Chair introduced the lead team, Dr Nabeel Alsindi, Rebecca Harmston and Mr Malcolm Oswald, who gave presentations on the clinical effectiveness and cost effectiveness of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

## **Part 2 – Closed session**

26. Discussion on confidential information continued. This information was supplied by the company.
27. The Committee continued to discuss the clinical and cost effectiveness of alectinib for untreated anaplastic lymphoma kinase positive advanced non-small-cell lung cancer.
  - 27.1. The committee decision was based on consensus.
28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## **Date, time and venue of the next meeting**

29. **Wednesday 11 April 2018, 10:00, at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.**